Equities Analysts Offer Predictions for ELDN Q2 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Noble Financial issued their Q2 2025 EPS estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. Noble Financial analyst R. Leboyer anticipates that the company will earn ($0.22) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.86) EPS.

Separately, Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Stock Performance

Shares of ELDN stock opened at $3.06 on Wednesday. Eledon Pharmaceuticals has a 1 year low of $2.30 and a 1 year high of $5.54. The stock has a fifty day moving average price of $3.15 and a 200 day moving average price of $3.92. The stock has a market cap of $183.24 million, a PE ratio of -1.52 and a beta of 0.08.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.20.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ELDN. Zimmer Partners LP lifted its stake in shares of Eledon Pharmaceuticals by 0.7% in the 1st quarter. Zimmer Partners LP now owns 754,970 shares of the company’s stock valued at $2,559,000 after purchasing an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Eledon Pharmaceuticals by 418.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after buying an additional 6,412 shares during the period. CW Advisors LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 1st quarter valued at about $34,000. Renaissance Technologies LLC lifted its position in Eledon Pharmaceuticals by 8.3% during the 4th quarter. Renaissance Technologies LLC now owns 147,173 shares of the company’s stock worth $606,000 after acquiring an additional 11,300 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Eledon Pharmaceuticals during the 1st quarter worth approximately $41,000. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).